Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)

NCT01428635 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01428635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01428635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2/3
Overall status
Completed
Start date
January 13, 2012
Completion date
January 3, 2022
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase chronic myelogenous leukemia, bcr-abl1 positive, blast phase chronic myelogenous leukemia, bcr-abl1 positive, chronic phase chronic myelogenous leukemia, bcr-abl1 positive, primary myelofibrosis, thrombocytopenia